Two major IPOs that will be in focus next week are Sudeep Pharma and Excelsoft Technologies. After the spectacular demand seen in recent big-ticket IPOs like big-ticket IPOs like Physics Wallah, Emvee Photovoltaic Power, and the Groww IPO, this week’s lineup is comparatively quieter, Sudeep Pharma IPO enters the final leg of its subscription with steady interest and a strong GMP trend, while Excelsoft Technologies IPO has already closed with exceptional oversubscription being at the centre of next week’s IPO activity.
Sudeep Pharma IPO Allotment & Listing
The Sudeep Pharma IPO, which opened for subscription this week, saw a good response across the investor category, and the IPO was oversubscribed 1.53 times. Next week the bidding window for the IPO will close, and after the successful allotment of shares, the Sudeep Pharma IPO will list on the BSE & NSE on November 28.
The 895 Cr issue comprises a fresh issue & OFS. The IPO price band is fixed at Rs. 563 to Rs. 593 per share. According to the latest data, the Sudeep Pharma IPO is expected to list with solid gains, as the current GMP stands at Rs. 115 as of November 22nd, which indicates that the Sudeep Pharma IPO listing price is around Rs. 708, indicating a potential 19.39% listing gain if current sentiment is sustained.
Excelsoft Technologies IPO Allotment & Listing
Another IPO which will be in the news next week is the Excelsoft Technologies IPO. In contrast to Sudeep Pharma, this IPO saw exceptional subscription demand, closing at 45.46 times on the final bidding day, November 21st.
The Excelsoft Technologies IPO is a Rs. 500.00 crore book-built issue with a price band set between Rs. 114 and Rs. 120 per share. The IPO opened on November 19, 2025, and closed on November 21, 2025. The Excelsoft Technologies IPO allotment date is scheduled for November 24, 2025, with a tentative listing on November 26, 2025, on the BSE and NSE.
As per the latest trend, the Excelsoft Technologies IPO GMP stood at Rs. 8 on November 22. This shows that the IPO will list around Rs. 128, translating into a potential 6.67% listing gain for the investors who receive their shares.